What is the serum (1→3)-β‑D‑glucan assay used for?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Serum β-D-Glucan Testing: Clinical Applications

Serum (1→3)-β-D-glucan (BDG) is primarily used as an adjunctive diagnostic test for invasive fungal diseases, particularly invasive candidiasis and Pneumocystis pneumonia, though it should not be used as the sole diagnostic criterion in critically ill patients. 1

Primary Clinical Indications

Invasive Candidiasis (IC)

  • BDG is most valuable for diagnosing invasive candidiasis in high-risk populations, including:

    • Hematological malignancy patients
    • Hematopoietic stem cell transplant recipients
    • Critically ill ICU patients
    • Solid organ transplant recipients
  • The test demonstrates sensitivity of 76-80% and specificity of 95-97% for IC 2

  • Critical caveat: In critically ill patients with suspected IC, the 2019 American Thoracic Society guidelines explicitly recommend NOT relying solely on BDG results for diagnostic decision-making (conditional recommendation, low-quality evidence) 1

Pneumocystis Pneumonia (PCP)

  • BDG shows excellent performance for PCP diagnosis, with pooled sensitivity of 96% and specificity of 84% 3
  • Particularly useful in HIV-positive patients (sensitivity 92%, specificity 78%) 4
  • A negative BDG effectively rules out PCP in HIV patients, making it an excellent screening tool 4, 3
  • In non-HIV immunocompromised patients, sensitivity drops to 85% with specificity of 73%, requiring correlation with clinical and radiological findings 4

Invasive Aspergillosis (IA)

  • BDG has a limited role as a standalone test for IA (sensitivity 57-76%, specificity 95-97%) 2
  • Galactomannan testing is preferred over BDG for aspergillosis 1, 5
  • BDG's value in IA lies primarily in combination with galactomannan or PCR, which improves diagnostic accuracy 2, 5

Diagnostic Performance Characteristics

Optimal Cutoff Values

  • Manufacturer cutoffs may not be optimal: Studies show improved performance at adjusted thresholds
    • Fungitell assay: Optimized at ≥120 pg/mL (vs. manufacturer's 80 pg/mL) 6
    • Wako assay: Optimized at ≥4 pg/mL (vs. manufacturer's ≥11 pg/mL) 6
    • Higher cutoffs (e.g., 142.4 pg/mL) reduce false positives while maintaining reasonable sensitivity 7

Test Characteristics by Population

  • Hematology patients: Sensitivity 50-70%, specificity 91-99% for invasive fungal disease 2
  • ICU/mixed populations: Sensitivity 78-85%, specificity 36-75%, with high negative predictive value (85-92%) 2
  • Overall for invasive fungal disease: Sensitivity 80%, specificity 82% 3

Organisms Detected vs. Not Detected

BDG-Positive Organisms:

  • Candida species
  • Aspergillus species
  • Pneumocystis jirovecii
  • Fusarium species
  • Trichosporon species

BDG-Negative Organisms (Critical to Know):

  • Cryptococcus species (absent/minimal BDG expression)
  • Mucorales (Rhizopus, Mucor)
  • Blastomyces species
  • These require alternative diagnostic approaches 8

Clinical Integration Strategy

When to Order BDG:

  1. High-risk patients with suspected invasive fungal disease:

    • Prolonged neutropenia
    • Hematological malignancy
    • Stem cell or solid organ transplant recipients
    • Prolonged ICU stay with risk factors
  2. Screening for PCP in immunocompromised patients (especially HIV-positive)

  3. As part of a multimodal diagnostic approach, not as a standalone test

Interpretation Algorithm:

For Suspected Invasive Candidiasis:

  • Positive BDG (≥120 pg/mL) + clinical suspicion → Initiate/continue antifungal therapy
  • Negative BDG → Consider stopping empirical antifungals (high NPV of 97-100%) 6, 7
  • Never rely on BDG alone in critically ill patients 1

For Suspected PCP:

  • Negative BDG in HIV patients → Effectively rules out PCP 4, 3
  • Positive BDG → Confirm with direct microscopy/PCR
  • In non-HIV patients → Must correlate with clinical/radiological findings 4

For Suspected Aspergillosis:

  • Order galactomannan first (preferred test) 1
  • Use BDG in combination with galactomannan or PCR to improve accuracy 2
  • BDG alone is insufficient for IA diagnosis

Important Caveats and False Positives

Sources of False Positives:

  • Bacterial infections: 21% false-positive rate with Fungitell assay 6
  • Hemodialysis with certain membranes (though modern membranes rarely cause this) 5
  • Gauze exposure during sample collection
  • Piperacillin-tazobactam use (significant correlation) 7
  • Mucositis in chemotherapy patients

Minimizing False Positives:

  • Use glucan-free collection equipment
  • Apply higher cutoff values (e.g., 120-142 pg/mL vs. 80 pg/mL) 6, 7
  • Interpret in clinical context with risk factors
  • Avoid testing in low pretest probability settings (reduces positive predictive value) 8

Practical Advantages

  • Rapid turnaround time: Results available within hours, faster than culture 1, 5
  • Pan-fungal detection: Detects multiple fungal pathogens simultaneously 5
  • High negative predictive value: Useful for antifungal stewardship—stopping unnecessary empirical therapy 7
  • Automated assays available: Newer chemiluminescence assays offer point-of-care testing potential 9

Role in Antifungal Stewardship

BDG's high negative predictive value (97-100%) makes it particularly valuable for discontinuing empirical antifungal therapy in patients without invasive fungal disease, reducing unnecessary drug exposure and costs 6, 7. However, this requires appropriate patient selection and should not be applied indiscriminately in low-risk populations where false positives predominate 8.

References

Research

Use of 1,3-β-D-glucan in invasive fungal diseases in hematology patients.

Expert review of anti-infective therapy, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.